Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Universite Pierre et Marie Curie discloses DNA gyrase inhibitors

Jan. 8, 2016

U.S. Army starts phase I trial of dengue challenge virus

Jan. 8, 2016

Vical's VL-2397 wins FDA orphan drug designation for invasive aspergillosis

Jan. 7, 2016

Inovio reports results from phase IIb trial of VGX-3100 in cervical intraepithelial neoplasia

Jan. 7, 2016

VenatoRx Pharmaceuticals presents beta-lactamase inhibitors

Jan. 7, 2016

FDA grants priority review to Gilead's NDA for sofosbuvir/velpatasvir

Jan. 5, 2016

Yisheng Biopharma releases phase I topline results for PIKA rabies vaccine

Jan. 5, 2016

Matinas BioPharma files IND application with FDA for MAT-2501

Jan. 5, 2016

Arbutus initiates phase IIa study of ARB-001467 for chronic HBV

Jan. 5, 2016

Gilead Sciences studies ledipasvir/sofosbuvir for chronic HCV and HBV coinfection

Jan. 4, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.